Oragenics, Inc. (NYSE American: OGEN) has entered into a significant partnership with Lantern Bioworks, marked by the formalization of a materials transfer agreement. This collaboration follows rigorous testing and validation of biological samples from Oragenics. These samples have the potential to revolutionize dental caries prevention by replacing harmful bacterial strains with non-pathogenic counterparts.

As part of this agreement, Oragenics has received a cash payment of $50,000 and an opportunity to acquire one million shares of Lantern Bioworks' equity. Additionally, Lantern Bioworks has committed to paying Oragenics a ten percent (10%) royalty on the net income generated from any products resulting from the transferred assets, spanning a ten-year term.

Kim Murphy, President and CEO of Oragenics, expressed enthusiasm for this development, highlighting the potential of these assets to address the global oral health challenge posed by dental caries.

It's important to note that these samples are distinct from Oragenics' current research endeavors, particularly in the fields of Lantibiotics or SARS-CoV-2 vaccine candidates. They originated from a previous research and development project that Oragenics had temporarily suspended, awaiting a suitable application.

Lantern Bioworks has a keen interest in leveraging the potential of these samples to enhance their ongoing product development initiatives. Importantly, this agreement does not involve the transfer of intellectual property ownership from Oragenics to Lantern Bioworks.